During the event, national opinion leaders shared important insights on diagnosing and personalizing the treatment of common skin conditions. Scientific moderators discussed interesting clinical cases and answered questions from the audience. Attendees also enjoyed a theatrical performance, festive dinner, exciting tours, and Christmas-themed shows in the charming city of Lviv.

While prioritizing therapy for the individual patient rather than the disease itself, adapting a personalized approach to established treatment protocols can be challenging. Therefore, modern physicians are responsible for considering the individual characteristics of the patient and, based on modern diagnostic methods, choosing the most appropriate systemic and local treatments.

The conference covered the following topics: An innovative approach to addressing immune-dependent dermatoses; The link between chronic inflammation and brain neuroregulatory processes; Treatment of psoriasis: what has changed in the last 5 years?; Aspects of modern trichology: new regulatory molecules for topical and systemic use; JAK inhibitors – new prospects for dermatology; Autoimmune blistering dermatoses – experience with immunobiological therapy.

Dermatological conditions are increasingly common, largely due to environmental factors, poor diet, lack of exercise, and constant stress.

The pharmaceutical company Ananta Medicare offers a range of products for the treatment and prevention of various dermatological conditions. One of these products is the antifungal medication Itrungar (caps. 100 mg No. 4 and No. 15), which is widely used by Ukrainian dermatologists to treat fungal skin infections such as onychomycosis, epidermophytosis, and rubrophytosis. Itrungar has a broad antifungal spectrum that targets all known pathogens causing these conditions, providing effective and reliable systemic treatment for fungal infections.

In recent years, the critical role of a healthy gut microbiome has been recognized as an etiological and pathogenetic factor in several dermatological diseases, including eczema, psoriasis, acne, and more. This highlights the importance of incorporating probiotics and symbiotic products in the treatment of these conditions. One such product is Lotardi-A.

Lotardi-A is a symbiotic formula containing Saccharomyces boulardii, a blend of lacto- and bifidobacteria supported by extensive clinical evidence and experience in EU countries, along with the enzyme alpha-amylase. Notably, it’s the only probiotic that includes alpha-amylase, which aids in digesting polysaccharides. The total number of live microorganisms is 14 billion.

Lotardi-A* is a unique symbiotic complex for protecting and restoring gut microflora